Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, single sequence, repeat dose study to investigate the effects of GSK 189075 [remogliflozin etabonate] on the pharmacokinetics of an oral contraceptive pill [ethinylestradiol/norethisterone] when coadministered to healthy female volunteers.

Next Previous
X
Search
Trial Profile

An open label, single sequence, repeat dose study to investigate the effects of GSK 189075 [remogliflozin etabonate] on the pharmacokinetics of an oral contraceptive pill [ethinylestradiol/norethisterone] when coadministered to healthy female volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remogliflozin etabonate (Primary) ; Ethinylestradiol/norethisterone
  • Indications Pregnancy
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 03 Feb 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 03 Feb 2010 Actual patient number (22) added as reported by ClinicalTrials.gov.
    • 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top